Wall Street brokerages forecast that Theravance Biopharma, Inc. (NASDAQ:TBPH) will post $13.19 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Theravance Biopharma’s earnings, with estimates ranging from $10.61 million to $18.44 million. Theravance Biopharma posted sales of $18.26 million in the same quarter last year, which would indicate a negative year over year growth rate of 27.8%. The company is scheduled to announce its next earnings report on Thursday, November 4th.
On average, analysts expect that Theravance Biopharma will report full-year sales of $55.75 million for the current financial year, with estimates ranging from $51.56 million to $67.37 million. For the next fiscal year, analysts anticipate that the firm will post sales of $134.03 million, with estimates ranging from $57.90 million to $330.71 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, August 2nd. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.22. The firm had revenue of $12.91 million during the quarter, compared to analyst estimates of $15.02 million.
A number of institutional investors have recently bought and sold shares of the business. Newbridge Financial Services Group Inc. acquired a new position in Theravance Biopharma in the 2nd quarter worth approximately $29,000. Walleye Capital LLC acquired a new position in Theravance Biopharma in the 2nd quarter worth approximately $242,000. Woodline Partners LP acquired a new position in Theravance Biopharma in the 2nd quarter worth approximately $5,444,000. Invesco Ltd. boosted its stake in Theravance Biopharma by 77.3% in the 2nd quarter. Invesco Ltd. now owns 21,812 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 9,508 shares during the period. Finally, Millennium Management LLC boosted its stake in Theravance Biopharma by 26.7% in the 2nd quarter. Millennium Management LLC now owns 150,551 shares of the biopharmaceutical company’s stock worth $2,186,000 after purchasing an additional 31,682 shares during the period. Hedge funds and other institutional investors own 82.11% of the company’s stock.
Shares of NASDAQ:TBPH traded up $0.25 during trading hours on Monday, hitting $7.11. The stock had a trading volume of 2,797,566 shares, compared to its average volume of 660,599. The stock’s fifty day simple moving average is $11.50 and its 200 day simple moving average is $16.22. Theravance Biopharma has a 1-year low of $6.10 and a 1-year high of $22.74. The firm has a market capitalization of $522.37 million, a price-to-earnings ratio of -1.73 and a beta of 0.82.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.